[HTML][HTML] Plasmodium vivax controlled human malaria infection–progress and prospects

RO Payne, PM Griffin, JS McCarthy, SJ Draper - Trends in parasitology, 2017 - cell.com
Trends in parasitology, 2017cell.com
Modern controlled human malaria infection (CHMI) clinical trials have almost entirely
focussed on Plasmodium falciparum, providing a highly informative means to investigate
host–pathogen interactions as well as assess potential new prophylactic and therapeutic
interventions. However, in recent years, there has been renewed interest in Plasmodium
vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This
review summarizes the published experiences, and examines the advantages and …
Modern controlled human malaria infection (CHMI) clinical trials have almost entirely focussed on Plasmodium falciparum, providing a highly informative means to investigate host–pathogen interactions as well as assess potential new prophylactic and therapeutic interventions. However, in recent years, there has been renewed interest in Plasmodium vivax, with CHMI models developed by groups in Colombia, the USA, and Australia. This review summarizes the published experiences, and examines the advantages and disadvantages of the different models that initiate infection either by mosquito bite or using a blood-stage inoculum. As for P. falciparum, CHMI studies with P. vivax will provide a platform for early proof-of-concept testing of drugs and vaccines, accelerating the development of novel interventions.
cell.com